For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? (Q47226622)

12 January 2018

meta-analysis

0 references

title

For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? (English)

1 reference

12 January 2018

1 reference

venous thromboembolism

1 reference

van der Heijden JF

1

1 reference

12 January 2018

Prins MH

series ordinal

2

1 reference

12 January 2018

Büller HR

series ordinal

3

1 reference

12 January 2018

publication date

1 October 2000

1 reference

12 January 2018

published in

Thrombosis Research

1 reference

12 January 2018

volume

100

1 reference

12 January 2018

issue

2

1 reference

12 January 2018

page(s)

V121-30

1 reference

12 January 2018

Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

1 reference

7 January 2021

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Diagnosis of heparin-induced thrombocytopenia. Still a journey, not yet a destination

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Low-molecular-weight heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Deep vein thrombosis of the legs: new therapy by means of low molecular weight heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

Low-molecular-weight heparin in the treatment of patients with venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900272-3

7 January 2021

10.1016/S0049-3848(00)00272-3

Identifiers

DOI

1 reference

12 January 2018

1 reference

12 January 2018